{"gene":"ASXL3","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2015,"finding":"ASXL3 physically interacts with BAP1, the catalytic subunit of the Polycomb Repressive Deubiquitination (PR-DUB) complex, and loss of ASXL3 in patient fibroblasts leads to a significant increase in histone H2AK119 mono-ubiquitination (H2AK119Ub1), demonstrating that ASXL3 is required for PR-DUB-mediated deubiquitination of H2A.","method":"Co-immunoprecipitation (Co-IP) of ASXL3 with BAP1; quantitative H2AK119Ub1 western blot in primary patient fibroblasts; transcriptome comparison by RNA-seq","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP establishing interaction, direct biochemical readout (H2AK119Ub1 increase) in patient cells with orthogonal transcriptome analysis, single lab","pmids":["26647312"],"is_preprint":false},{"year":2020,"finding":"ASXL3 functions as an adaptor/scaffold protein that directly bridges BRD4 to the BAP1 complex in SCLC-A cells: ASXL3 interacts with BRD4's extra-terminal (ET) domain via a novel BRD4-binding motif (BBM), and this interaction maintains chromatin occupancy of BRD4 at active enhancers; genetic depletion of ASXL3 causes genome-wide reduction of H3K27Ac levels and BRD4-dependent gene expression.","method":"Size exclusion chromatography, mass spectrometry, western blot for protein-protein interaction; ChIP-seq for BRD4 and H3K27Ac; RNA-seq; ASXL3 genetic depletion","journal":"Genome medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal biochemical methods (SEC, MS, co-IP/western) plus functional genomics (ChIP-seq, RNA-seq) with genetic depletion, single lab","pmids":["32669118"],"is_preprint":false},{"year":2022,"finding":"Pharmacologic inhibition of BAP1 catalytic activity with iBAP-II disrupts the BAP1/ASXL3/BRD4 epigenetic axis by inducing protein degradation of the ASXL3 scaffold protein, and represses ASCL1/MYCL/E2F neuroendocrine transcriptional programs in SCLC cells, inhibiting cell viability and tumor growth in vivo.","method":"BAP1 inhibitor treatment (iBAP-II); western blot for ASXL3 protein levels; cell viability assays; in vivo xenograft tumor growth experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic perturbation with defined molecular readout (ASXL3 degradation) and in vivo validation, single lab, abstract-level description","pmids":["35194152"],"is_preprint":false},{"year":2014,"finding":"ASXL3 interacts with HP1α and LSD1 and acts as a transcriptional corepressor of LXRα and TRβ: ligand-dependent physical interactions between ASXL3 and LXRα/TRβ were demonstrated, ASXL3 is recruited to LXR-response elements to suppress LXRα target gene expression, and ASXL3 overexpression reduces lipid accumulation while ASXL3 depletion increases it in Hep3B cells.","method":"GST pull-down; immunoprecipitation; chromatin immunoprecipitation (ChIP) at LXR-response elements; ASXL3 overexpression and depletion with gene expression and lipid accumulation assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple orthogonal methods (GST pulldown, co-IP, ChIP, gain/loss-of-function) in single lab; interaction and functional consequence established","pmids":["25450400"],"is_preprint":false},{"year":2015,"finding":"ASXL3 harbors ASXN, ASXM and PHD domains (consistent with Polycomb-group scaffold function), and truncating mutations in BRS patient fibroblasts produce ASXL3 mRNA subject to nonsense-mediated decay, reducing ASXL3 protein expression and disrupting H2AK119Ub1 regulation.","method":"RT-PCR/mRNA analysis for nonsense-mediated decay; western blot for ASXL3 protein; H2AK119Ub1 western blot in patient-derived fibroblasts","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mRNA and protein analysis in patient cells with orthogonal biochemical readout, single lab","pmids":["26647312"],"is_preprint":false},{"year":2017,"finding":"ASXL3 silencing in lung iPSCs and SCLC cell lines inhibits proliferation, clonogenicity, and teratoma formation, and reduces malignant growth in vivo, consistent with a role for ASXL3 in sustaining stem/proliferative transcriptional programs associated with PRC2.","method":"ASXL3 siRNA/shRNA knockdown; cell proliferation and clonogenicity assays; in vivo teratoma and xenograft formation","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined proliferative phenotype and in vivo readout, single lab, abstract-level mechanistic placement","pmids":["28935813"],"is_preprint":false},{"year":2023,"finding":"ASXL3 compound heterozygous mutations in mouse cardiomyocytes upregulate lncRNA NONMMUT063967.2, which suppresses FGFR2 expression and inhibits the Ras/ERK signaling pathway, leading to reduced cell proliferation and increased apoptosis; silencing of lncRNA NONMMUT063967.2 or overexpression of FGFR2 reverses these effects.","method":"lncRNA/mRNA sequencing; CCK8 and flow cytometry assays; qRT-PCR and western blot; lncRNA silencing and FGFR2 overexpression rescue experiments in HL-1 cells","journal":"Biochemistry and biophysics reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell-line model, mechanism inferred from overexpression of mutant ASXL3, functional placement partially abstract-level","pmids":["37435360"],"is_preprint":false}],"current_model":"ASXL3 is a chromatin-associated scaffold protein that associates with BAP1 as a component of the Polycomb Repressive Deubiquitination (PR-DUB) complex to promote removal of H2AK119 mono-ubiquitin, acts as an adaptor bridging BRD4 to the BAP1 complex at active enhancers via a direct interaction with BRD4's extra-terminal domain, and also functions as a transcriptional corepressor of nuclear receptors (LXRα, TRβ) through recruitment of HP1α and LSD1; loss-of-function truncating mutations reduce ASXL3 protein via nonsense-mediated decay, elevate H2AK119Ub1, and dysregulate gene expression programs relevant to neurodevelopment and oncogenesis."},"narrative":{"mechanistic_narrative":"ASXL3 is a chromatin-associated scaffold protein that controls histone H2A mono-ubiquitination and enhancer-dependent transcription with consequences for neurodevelopment and tumor growth [PMID:26647312, PMID:32669118]. It physically associates with BAP1, the catalytic subunit of the Polycomb Repressive Deubiquitination (PR-DUB) complex, and is required for PR-DUB-mediated removal of H2AK119 mono-ubiquitin: loss of ASXL3 in patient fibroblasts elevates H2AK119Ub1 and dysregulates the transcriptome [PMID:26647312]. ASXL3 additionally acts as an adaptor that directly bridges BRD4 to the BAP1 complex, binding the BRD4 extra-terminal domain through a dedicated BRD4-binding motif to maintain BRD4 occupancy and H3K27Ac at active enhancers; its depletion reduces genome-wide H3K27Ac and BRD4-dependent gene expression [PMID:32669118]. Pharmacologic inhibition of BAP1 catalytic activity destabilizes the ASXL3 scaffold and collapses ASCL1/MYCL/E2F neuroendocrine programs, impairing small-cell lung cancer viability and tumor growth [PMID:35194152]. Independently, ASXL3 serves as a ligand-dependent transcriptional corepressor of the nuclear receptors LXRα and TRβ, recruiting HP1α and LSD1 to response elements and restraining LXRα target genes and lipid accumulation [PMID:25450400]. Truncating mutations in Bainbridge-Ropers syndrome patients produce ASXL3 transcripts subject to nonsense-mediated decay, lowering ASXL3 protein and disrupting H2AK119Ub1 regulation [PMID:26647312].","teleology":[{"year":2014,"claim":"Before its chromatin-complex role was defined, it was unknown how ASXL3 influenced transcription; this work established it as a ligand-dependent corepressor of nuclear receptors coupled to chromatin-modifying machinery.","evidence":"GST pull-down, co-IP, and ChIP at LXR-response elements with gain/loss-of-function and lipid assays in Hep3B cells","pmids":["25450400"],"confidence":"Medium","gaps":["Does not connect this corepressor activity to the PR-DUB/BAP1 axis","Structural basis of HP1α/LSD1 recruitment unresolved","Single cell-line model"]},{"year":2015,"claim":"It was unclear which chromatin complex ASXL3 operated in; demonstrating BAP1 interaction and elevated H2AK119Ub1 upon ASXL3 loss placed it within the PR-DUB complex as a required deubiquitination cofactor.","evidence":"Reciprocal Co-IP of ASXL3 with BAP1 and quantitative H2AK119Ub1 western blot with RNA-seq in patient fibroblasts","pmids":["26647312"],"confidence":"High","gaps":["Stoichiometry and assembly of ASXL3 within PR-DUB not defined","Genome-wide H2AK119Ub1 occupancy not mapped","Direct vs indirect deubiquitination requirement not separated"]},{"year":2015,"claim":"How disease-associated mutations impair ASXL3 was unknown; showing truncating mutations trigger nonsense-mediated decay established a loss-of-function mechanism reducing protein and disrupting H2AK119Ub1 control.","evidence":"RT-PCR/mRNA NMD analysis, ASXL3 protein western, and H2AK119Ub1 western in BRS patient-derived fibroblasts; domain annotation (ASXN, ASXM, PHD)","pmids":["26647312"],"confidence":"Medium","gaps":["Functional contribution of individual ASXN/ASXM/PHD domains untested","Dominant-negative vs haploinsufficiency not distinguished","Neurodevelopmental phenotype link inferred, not modeled"]},{"year":2017,"claim":"Whether ASXL3 sustains proliferative programs in tumors was open; silencing experiments showed it is required for proliferation, clonogenicity, and malignant growth in lung-derived cells.","evidence":"siRNA/shRNA knockdown with proliferation, clonogenicity, teratoma, and xenograft assays in iPSCs and SCLC lines","pmids":["28935813"],"confidence":"Medium","gaps":["Mechanistic link to PR-DUB or PRC2 placement remains abstract-level","Direct target genes not defined here","Single lab"]},{"year":2020,"claim":"It was unknown how ASXL3 connected the BAP1 complex to active transcription; identifying a direct BRD4 ET-domain interaction defined ASXL3 as an adaptor maintaining BRD4 enhancer occupancy and H3K27Ac.","evidence":"SEC, mass spectrometry, co-IP/western for the BBM-ET interaction plus BRD4/H3K27Ac ChIP-seq and RNA-seq under ASXL3 depletion in SCLC-A cells","pmids":["32669118"],"confidence":"High","gaps":["Structural detail of the BBM-ET interface not resolved","Whether BRD4 bridging is generalizable beyond SCLC-A untested","Interplay between deubiquitination and BRD4 recruitment unresolved"]},{"year":2022,"claim":"Whether the BAP1/ASXL3/BRD4 axis is pharmacologically tractable was untested; BAP1 catalytic inhibition was shown to degrade the ASXL3 scaffold and repress neuroendocrine programs, identifying a therapeutic vulnerability.","evidence":"iBAP-II treatment with ASXL3 protein western, viability assays, and in vivo xenograft tumor growth in SCLC","pmids":["35194152"],"confidence":"Medium","gaps":["Mechanism linking BAP1 catalysis to ASXL3 stability not defined","Abstract-level description","Off-target effects of iBAP-II not excluded"]},{"year":2023,"claim":"How ASXL3 mutations impair cardiac cells was unknown; a compound-heterozygous model implicated an lncRNA-FGFR2-Ras/ERK axis controlling proliferation and apoptosis.","evidence":"lncRNA/mRNA-seq, CCK8/flow cytometry, and lncRNA-silencing/FGFR2-rescue experiments in HL-1 cardiomyocytes","pmids":["37435360"],"confidence":"Low","gaps":["Single cell-line model with mechanism inferred from mutant overexpression","Direct chromatin mechanism connecting ASXL3 to the lncRNA not shown","Relevance to human cardiac disease unconfirmed"]},{"year":null,"claim":"How ASXL3's distinct activities — PR-DUB deubiquitination, BRD4 enhancer bridging, and nuclear-receptor corepression — are coordinated on chromatin and which is decisive for neurodevelopmental versus oncogenic outcomes remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of ASXL3 in any complex","Domain-resolved contributions to each function untested","No in vivo model integrating chromatin and disease phenotypes"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,3]}],"complexes":["PR-DUB"],"partners":["BAP1","BRD4","HP1A","LSD1","NR1H3","THRB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9C0F0","full_name":"Putative Polycomb group protein ASXL3","aliases":["Additional sex combs-like protein 3"],"length_aa":2248,"mass_kda":241.9,"function":"Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity). Non-catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1) (PubMed:30664650, PubMed:36180891). The PR-DUB complex is an epigenetic regulator of gene expression and acts as a transcriptional coactivator, affecting genes involved in development, cell communication, signaling, cell proliferation and cell viability (PubMed:30664650, PubMed:36180891). ASXL1, ASXL2 and ASXL3 function redundantly in the PR-DUB complex and are essential for chromatin recruitment and transcriptional activation of associated genes (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9C0F0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ASXL3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ASXL3","total_profiled":1310},"omim":[{"mim_id":"617190","title":"SHASHI-PENA SYNDROME; SHAPNS","url":"https://www.omim.org/entry/617190"},{"mim_id":"615485","title":"BAINBRIDGE-ROPERS SYNDROME; BRPS","url":"https://www.omim.org/entry/615485"},{"mim_id":"615115","title":"ASXL TRANSCRIPTIONAL REGULATOR 3; ASXL3","url":"https://www.omim.org/entry/615115"},{"mim_id":"607375","title":"DOT1-LIKE; DOT1L","url":"https://www.omim.org/entry/607375"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in some","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ASXL3"},"hgnc":{"alias_symbol":[],"prev_symbol":["KIAA1713"]},"alphafold":{"accession":"Q9C0F0","domains":[{"cath_id":"-","chopping":"258-347","consensus_level":"medium","plddt":86.1651,"start":258,"end":347},{"cath_id":"-","chopping":"2216-2248","consensus_level":"medium","plddt":55.5482,"start":2216,"end":2248},{"cath_id":"1.10.10","chopping":"2-87","consensus_level":"medium","plddt":80.0378,"start":2,"end":87}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9C0F0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9C0F0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9C0F0-F1-predicted_aligned_error_v6.png","plddt_mean":39.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ASXL3","jax_strain_url":"https://www.jax.org/strain/search?query=ASXL3"},"sequence":{"accession":"Q9C0F0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9C0F0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9C0F0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9C0F0"}},"corpus_meta":[{"pmid":"26647312","id":"PMC_26647312","title":"De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26647312","citation_count":63,"is_preprint":false},{"pmid":"15138607","id":"PMC_15138607","title":"Identification and characterization of ASXL3 gene in silico.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15138607","citation_count":60,"is_preprint":false},{"pmid":"28100473","id":"PMC_28100473","title":"Delineating the phenotypic spectrum of Bainbridge-Ropers syndrome: 12 new patients with de novo, heterozygous, loss-of-function mutations in ASXL3 and review of published literature.","date":"2017","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28100473","citation_count":54,"is_preprint":false},{"pmid":"25835095","id":"PMC_25835095","title":"Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.","date":"2015","source":"Expert review of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/25835095","citation_count":52,"is_preprint":false},{"pmid":"32669118","id":"PMC_32669118","title":"ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.","date":"2020","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32669118","citation_count":51,"is_preprint":false},{"pmid":"24044690","id":"PMC_24044690","title":"De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies.","date":"2013","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24044690","citation_count":47,"is_preprint":false},{"pmid":"27901041","id":"PMC_27901041","title":"Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition.","date":"2016","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/27901041","citation_count":44,"is_preprint":false},{"pmid":"29305346","id":"PMC_29305346","title":"A de novo nonsense mutation in ASXL3 shared by siblings with Bainbridge-Ropers syndrome.","date":"2018","source":"Cold Spring Harbor molecular case studies","url":"https://pubmed.ncbi.nlm.nih.gov/29305346","citation_count":37,"is_preprint":false},{"pmid":"27075689","id":"PMC_27075689","title":"Novel splicing mutation in the ASXL3 gene causing Bainbridge-Ropers syndrome.","date":"2016","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/27075689","citation_count":30,"is_preprint":false},{"pmid":"35194152","id":"PMC_35194152","title":"Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35194152","citation_count":26,"is_preprint":false},{"pmid":"32696347","id":"PMC_32696347","title":"Compound heterozygous mutation of the ASXL3 gene causes autosomal recessive congenital heart disease.","date":"2020","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32696347","citation_count":23,"is_preprint":false},{"pmid":"34436830","id":"PMC_34436830","title":"Expanding the phenotype of ASXL3-related syndrome: A comprehensive description of 45 unpublished individuals with inherited and de novo pathogenic variants in ASXL3.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/34436830","citation_count":22,"is_preprint":false},{"pmid":"28935813","id":"PMC_28935813","title":"ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28935813","citation_count":22,"is_preprint":false},{"pmid":"31180560","id":"PMC_31180560","title":"Novel de novo frameshift variant in the ASXL3 gene in a child with microcephaly and global developmental delay.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/31180560","citation_count":16,"is_preprint":false},{"pmid":"36177608","id":"PMC_36177608","title":"Familial Bainbridge-Ropers syndrome: Report of familial ASXL3 inheritance and a milder phenotype.","date":"2022","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/36177608","citation_count":15,"is_preprint":false},{"pmid":"32240826","id":"PMC_32240826","title":"Mosaicism in ASXL3-related syndrome: Description of five patients from three families.","date":"2020","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32240826","citation_count":14,"is_preprint":false},{"pmid":"32517662","id":"PMC_32517662","title":"Bainbridge-ropers syndrome caused by loss-of-function variants in ASXL3: Clinical abnormalities, medical imaging features, and gene variation in infancy of case report.","date":"2020","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/32517662","citation_count":12,"is_preprint":false},{"pmid":"28785287","id":"PMC_28785287","title":"Novel compound heterozygous ASXL3 mutation causing Bainbridge-ropers like syndrome and primary IGF1 deficiency.","date":"2017","source":"International journal of pediatric endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28785287","citation_count":10,"is_preprint":false},{"pmid":"38420660","id":"PMC_38420660","title":"ASXL3-related disorder: Molecular phenotyping and comprehensive review providing insights into disease mechanism.","date":"2024","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38420660","citation_count":9,"is_preprint":false},{"pmid":"25450400","id":"PMC_25450400","title":"Repression of LXRα by a novel member of additional sex comb-like family, ASXL3.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25450400","citation_count":9,"is_preprint":false},{"pmid":"29445472","id":"PMC_29445472","title":"Mild prominence of the Sylvian fissure in a Bainbridge-Ropers syndrome patient with a novel frameshift variant in ASXL3.","date":"2017","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/29445472","citation_count":9,"is_preprint":false},{"pmid":"35276034","id":"PMC_35276034","title":"De novo nonsense variant in ASXL3 in a Chinese girl causing Bainbridge-Ropers syndrome: A case report and review of literature.","date":"2022","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35276034","citation_count":8,"is_preprint":false},{"pmid":"29429203","id":"PMC_29429203","title":"[Bainbridge-Ropers syndrome with ASXL3 gene variation in a child and literature review].","date":"2018","source":"Zhonghua er ke za zhi = Chinese journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/29429203","citation_count":7,"is_preprint":false},{"pmid":"29628764","id":"PMC_29628764","title":"Phenotypic characterization of an older adult male with late-onset epilepsy and a novel mutation in ASXL3 shows overlap with the associated Bainbridge-Ropers syndrome.","date":"2018","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/29628764","citation_count":6,"is_preprint":false},{"pmid":"33392332","id":"PMC_33392332","title":"Novel mutation in the ASXL3 gene in a Chinese boy with microcephaly and speech impairment: A case report.","date":"2020","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/33392332","citation_count":5,"is_preprint":false},{"pmid":"39610869","id":"PMC_39610869","title":"Four heterozygous de novo variants in ASXL3 identified with Bainbridge-Ropers syndrome and further dissecting published genotype-phenotype spectrum.","date":"2024","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/39610869","citation_count":5,"is_preprint":false},{"pmid":"31638014","id":"PMC_31638014","title":"Novel Nonsense Mutation in ASXL3 causing Bainbridge-Ropers Syndrome.","date":"2019","source":"Indian pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/31638014","citation_count":5,"is_preprint":false},{"pmid":"37435360","id":"PMC_37435360","title":"ASXL3 gene mutations inhibit cell proliferation and promote cell apoptosis in mouse cardiomyocytes by upregulating lncRNA NONMMUT063967.2.","date":"2023","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/37435360","citation_count":3,"is_preprint":false},{"pmid":"35863334","id":"PMC_35863334","title":"ASXL3 De Novo Variant-Related Neurodevelopmental Disorder Presenting as Dystonic Cerebral Palsy.","date":"2022","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/35863334","citation_count":3,"is_preprint":false},{"pmid":"34886823","id":"PMC_34886823","title":"Case report : a novel ASXL3 gene variant in a Sudanese boy.","date":"2021","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34886823","citation_count":3,"is_preprint":false},{"pmid":"40891523","id":"PMC_40891523","title":"Speech and Language Development of Two Brothers With Bainbridge-Ropers Syndrome: Phenotypic and Bioinformatic Support for a Cerebellar ASXL3 Hypothesis.","date":"2025","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/40891523","citation_count":3,"is_preprint":false},{"pmid":"33751541","id":"PMC_33751541","title":"[Analysis of ASXL3 gene variant in a child with Bainbridge-Ropers syndrome].","date":"2021","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33751541","citation_count":3,"is_preprint":false},{"pmid":"34247375","id":"PMC_34247375","title":"[A case of Bainbridge-Ropers syndrome with autism in conjunct with ASXL3 gene variant and its clinical analysis].","date":"2021","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34247375","citation_count":2,"is_preprint":false},{"pmid":"39097281","id":"PMC_39097281","title":"[Report of a child with Bainbridge-Ropers syndrome due to a novel variant of ASXL3 gene and a literature review].","date":"2024","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39097281","citation_count":1,"is_preprint":false},{"pmid":"40980137","id":"PMC_40980137","title":"Paternal mosaicism in ASXL3-related bainbridge-ropers syndrome: implications for genetic counseling and prenatal diagnosis.","date":"2025","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/40980137","citation_count":1,"is_preprint":false},{"pmid":"32219835","id":"PMC_32219835","title":"[Diagnosis of Bainbridge-Ropers syndrome due to de novo ASXL3 variant by high throughput sequencing].","date":"2020","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32219835","citation_count":1,"is_preprint":false},{"pmid":"41146021","id":"PMC_41146021","title":"A novel ASXL3 gene variant in a Chinese Boy causing Bainbridge.","date":"2025","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/41146021","citation_count":0,"is_preprint":false},{"pmid":"41659201","id":"PMC_41659201","title":"ASXL3 gene variants causing Bainbridge-Ropers syndrome: clinical and genetic analysis of four Chinese patients.","date":"2026","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/41659201","citation_count":0,"is_preprint":false},{"pmid":"41458212","id":"PMC_41458212","title":"Case Report: Synergistic effects of an ASXL3 mutation and a 15q11.2 BP1-BP2 microdeletion in a severe neurodevelopmental phenotype.","date":"2025","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41458212","citation_count":0,"is_preprint":false},{"pmid":"42194125","id":"PMC_42194125","title":"Studying Familial Bainbridge-Ropers Syndrome Due to a Novel ASXL3 Germline Variant and Expanding the Clinical Spectrum.","date":"2026","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/42194125","citation_count":0,"is_preprint":false},{"pmid":"41584925","id":"PMC_41584925","title":"Correction: Case Report: Synergistic effects of an ASXL3 mutation and a 15q11.2 BP1-BP2 microdeletion in a severe neurodevelopmental phenotype.","date":"2026","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41584925","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.28.691117","title":"BAP1 dysregulation impairs trophoblast differentiation and contributes to placental dysfunction in preeclampsia","date":"2025-12-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.28.691117","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.19.24312213","title":"The LMSz method - an automatable scalable approach to constructing gene-specific growth charts in rare disorders","date":"2024-08-20","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.19.24312213","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21908,"output_tokens":2141,"usd":0.048919,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9091,"output_tokens":3153,"usd":0.06214,"stage2_stop_reason":"end_turn"},"total_usd":0.111059,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"ASXL3 physically interacts with BAP1, the catalytic subunit of the Polycomb Repressive Deubiquitination (PR-DUB) complex, and loss of ASXL3 in patient fibroblasts leads to a significant increase in histone H2AK119 mono-ubiquitination (H2AK119Ub1), demonstrating that ASXL3 is required for PR-DUB-mediated deubiquitination of H2A.\",\n      \"method\": \"Co-immunoprecipitation (Co-IP) of ASXL3 with BAP1; quantitative H2AK119Ub1 western blot in primary patient fibroblasts; transcriptome comparison by RNA-seq\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP establishing interaction, direct biochemical readout (H2AK119Ub1 increase) in patient cells with orthogonal transcriptome analysis, single lab\",\n      \"pmids\": [\"26647312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASXL3 functions as an adaptor/scaffold protein that directly bridges BRD4 to the BAP1 complex in SCLC-A cells: ASXL3 interacts with BRD4's extra-terminal (ET) domain via a novel BRD4-binding motif (BBM), and this interaction maintains chromatin occupancy of BRD4 at active enhancers; genetic depletion of ASXL3 causes genome-wide reduction of H3K27Ac levels and BRD4-dependent gene expression.\",\n      \"method\": \"Size exclusion chromatography, mass spectrometry, western blot for protein-protein interaction; ChIP-seq for BRD4 and H3K27Ac; RNA-seq; ASXL3 genetic depletion\",\n      \"journal\": \"Genome medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal biochemical methods (SEC, MS, co-IP/western) plus functional genomics (ChIP-seq, RNA-seq) with genetic depletion, single lab\",\n      \"pmids\": [\"32669118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Pharmacologic inhibition of BAP1 catalytic activity with iBAP-II disrupts the BAP1/ASXL3/BRD4 epigenetic axis by inducing protein degradation of the ASXL3 scaffold protein, and represses ASCL1/MYCL/E2F neuroendocrine transcriptional programs in SCLC cells, inhibiting cell viability and tumor growth in vivo.\",\n      \"method\": \"BAP1 inhibitor treatment (iBAP-II); western blot for ASXL3 protein levels; cell viability assays; in vivo xenograft tumor growth experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic perturbation with defined molecular readout (ASXL3 degradation) and in vivo validation, single lab, abstract-level description\",\n      \"pmids\": [\"35194152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ASXL3 interacts with HP1α and LSD1 and acts as a transcriptional corepressor of LXRα and TRβ: ligand-dependent physical interactions between ASXL3 and LXRα/TRβ were demonstrated, ASXL3 is recruited to LXR-response elements to suppress LXRα target gene expression, and ASXL3 overexpression reduces lipid accumulation while ASXL3 depletion increases it in Hep3B cells.\",\n      \"method\": \"GST pull-down; immunoprecipitation; chromatin immunoprecipitation (ChIP) at LXR-response elements; ASXL3 overexpression and depletion with gene expression and lipid accumulation assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple orthogonal methods (GST pulldown, co-IP, ChIP, gain/loss-of-function) in single lab; interaction and functional consequence established\",\n      \"pmids\": [\"25450400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ASXL3 harbors ASXN, ASXM and PHD domains (consistent with Polycomb-group scaffold function), and truncating mutations in BRS patient fibroblasts produce ASXL3 mRNA subject to nonsense-mediated decay, reducing ASXL3 protein expression and disrupting H2AK119Ub1 regulation.\",\n      \"method\": \"RT-PCR/mRNA analysis for nonsense-mediated decay; western blot for ASXL3 protein; H2AK119Ub1 western blot in patient-derived fibroblasts\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mRNA and protein analysis in patient cells with orthogonal biochemical readout, single lab\",\n      \"pmids\": [\"26647312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ASXL3 silencing in lung iPSCs and SCLC cell lines inhibits proliferation, clonogenicity, and teratoma formation, and reduces malignant growth in vivo, consistent with a role for ASXL3 in sustaining stem/proliferative transcriptional programs associated with PRC2.\",\n      \"method\": \"ASXL3 siRNA/shRNA knockdown; cell proliferation and clonogenicity assays; in vivo teratoma and xenograft formation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined proliferative phenotype and in vivo readout, single lab, abstract-level mechanistic placement\",\n      \"pmids\": [\"28935813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ASXL3 compound heterozygous mutations in mouse cardiomyocytes upregulate lncRNA NONMMUT063967.2, which suppresses FGFR2 expression and inhibits the Ras/ERK signaling pathway, leading to reduced cell proliferation and increased apoptosis; silencing of lncRNA NONMMUT063967.2 or overexpression of FGFR2 reverses these effects.\",\n      \"method\": \"lncRNA/mRNA sequencing; CCK8 and flow cytometry assays; qRT-PCR and western blot; lncRNA silencing and FGFR2 overexpression rescue experiments in HL-1 cells\",\n      \"journal\": \"Biochemistry and biophysics reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell-line model, mechanism inferred from overexpression of mutant ASXL3, functional placement partially abstract-level\",\n      \"pmids\": [\"37435360\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ASXL3 is a chromatin-associated scaffold protein that associates with BAP1 as a component of the Polycomb Repressive Deubiquitination (PR-DUB) complex to promote removal of H2AK119 mono-ubiquitin, acts as an adaptor bridging BRD4 to the BAP1 complex at active enhancers via a direct interaction with BRD4's extra-terminal domain, and also functions as a transcriptional corepressor of nuclear receptors (LXRα, TRβ) through recruitment of HP1α and LSD1; loss-of-function truncating mutations reduce ASXL3 protein via nonsense-mediated decay, elevate H2AK119Ub1, and dysregulate gene expression programs relevant to neurodevelopment and oncogenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ASXL3 is a chromatin-associated scaffold protein that controls histone H2A mono-ubiquitination and enhancer-dependent transcription with consequences for neurodevelopment and tumor growth [#0, #1]. It physically associates with BAP1, the catalytic subunit of the Polycomb Repressive Deubiquitination (PR-DUB) complex, and is required for PR-DUB-mediated removal of H2AK119 mono-ubiquitin: loss of ASXL3 in patient fibroblasts elevates H2AK119Ub1 and dysregulates the transcriptome [#0]. ASXL3 additionally acts as an adaptor that directly bridges BRD4 to the BAP1 complex, binding the BRD4 extra-terminal domain through a dedicated BRD4-binding motif to maintain BRD4 occupancy and H3K27Ac at active enhancers; its depletion reduces genome-wide H3K27Ac and BRD4-dependent gene expression [#1]. Pharmacologic inhibition of BAP1 catalytic activity destabilizes the ASXL3 scaffold and collapses ASCL1/MYCL/E2F neuroendocrine programs, impairing small-cell lung cancer viability and tumor growth [#2]. Independently, ASXL3 serves as a ligand-dependent transcriptional corepressor of the nuclear receptors LXR\\u03b1 and TR\\u03b2, recruiting HP1\\u03b1 and LSD1 to response elements and restraining LXR\\u03b1 target genes and lipid accumulation [#3]. Truncating mutations in Bainbridge-Ropers syndrome patients produce ASXL3 transcripts subject to nonsense-mediated decay, lowering ASXL3 protein and disrupting H2AK119Ub1 regulation [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Before its chromatin-complex role was defined, it was unknown how ASXL3 influenced transcription; this work established it as a ligand-dependent corepressor of nuclear receptors coupled to chromatin-modifying machinery.\",\n      \"evidence\": \"GST pull-down, co-IP, and ChIP at LXR-response elements with gain/loss-of-function and lipid assays in Hep3B cells\",\n      \"pmids\": [\"25450400\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not connect this corepressor activity to the PR-DUB/BAP1 axis\", \"Structural basis of HP1\\u03b1/LSD1 recruitment unresolved\", \"Single cell-line model\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"It was unclear which chromatin complex ASXL3 operated in; demonstrating BAP1 interaction and elevated H2AK119Ub1 upon ASXL3 loss placed it within the PR-DUB complex as a required deubiquitination cofactor.\",\n      \"evidence\": \"Reciprocal Co-IP of ASXL3 with BAP1 and quantitative H2AK119Ub1 western blot with RNA-seq in patient fibroblasts\",\n      \"pmids\": [\"26647312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and assembly of ASXL3 within PR-DUB not defined\", \"Genome-wide H2AK119Ub1 occupancy not mapped\", \"Direct vs indirect deubiquitination requirement not separated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"How disease-associated mutations impair ASXL3 was unknown; showing truncating mutations trigger nonsense-mediated decay established a loss-of-function mechanism reducing protein and disrupting H2AK119Ub1 control.\",\n      \"evidence\": \"RT-PCR/mRNA NMD analysis, ASXL3 protein western, and H2AK119Ub1 western in BRS patient-derived fibroblasts; domain annotation (ASXN, ASXM, PHD)\",\n      \"pmids\": [\"26647312\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional contribution of individual ASXN/ASXM/PHD domains untested\", \"Dominant-negative vs haploinsufficiency not distinguished\", \"Neurodevelopmental phenotype link inferred, not modeled\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Whether ASXL3 sustains proliferative programs in tumors was open; silencing experiments showed it is required for proliferation, clonogenicity, and malignant growth in lung-derived cells.\",\n      \"evidence\": \"siRNA/shRNA knockdown with proliferation, clonogenicity, teratoma, and xenograft assays in iPSCs and SCLC lines\",\n      \"pmids\": [\"28935813\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link to PR-DUB or PRC2 placement remains abstract-level\", \"Direct target genes not defined here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"It was unknown how ASXL3 connected the BAP1 complex to active transcription; identifying a direct BRD4 ET-domain interaction defined ASXL3 as an adaptor maintaining BRD4 enhancer occupancy and H3K27Ac.\",\n      \"evidence\": \"SEC, mass spectrometry, co-IP/western for the BBM-ET interaction plus BRD4/H3K27Ac ChIP-seq and RNA-seq under ASXL3 depletion in SCLC-A cells\",\n      \"pmids\": [\"32669118\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of the BBM-ET interface not resolved\", \"Whether BRD4 bridging is generalizable beyond SCLC-A untested\", \"Interplay between deubiquitination and BRD4 recruitment unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Whether the BAP1/ASXL3/BRD4 axis is pharmacologically tractable was untested; BAP1 catalytic inhibition was shown to degrade the ASXL3 scaffold and repress neuroendocrine programs, identifying a therapeutic vulnerability.\",\n      \"evidence\": \"iBAP-II treatment with ASXL3 protein western, viability assays, and in vivo xenograft tumor growth in SCLC\",\n      \"pmids\": [\"35194152\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking BAP1 catalysis to ASXL3 stability not defined\", \"Abstract-level description\", \"Off-target effects of iBAP-II not excluded\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"How ASXL3 mutations impair cardiac cells was unknown; a compound-heterozygous model implicated an lncRNA-FGFR2-Ras/ERK axis controlling proliferation and apoptosis.\",\n      \"evidence\": \"lncRNA/mRNA-seq, CCK8/flow cytometry, and lncRNA-silencing/FGFR2-rescue experiments in HL-1 cardiomyocytes\",\n      \"pmids\": [\"37435360\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single cell-line model with mechanism inferred from mutant overexpression\", \"Direct chromatin mechanism connecting ASXL3 to the lncRNA not shown\", \"Relevance to human cardiac disease unconfirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ASXL3's distinct activities — PR-DUB deubiquitination, BRD4 enhancer bridging, and nuclear-receptor corepression — are coordinated on chromatin and which is decisive for neurodevelopmental versus oncogenic outcomes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of ASXL3 in any complex\", \"Domain-resolved contributions to each function untested\", \"No in vivo model integrating chromatin and disease phenotypes\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"complexes\": [\"PR-DUB\"],\n    \"partners\": [\"BAP1\", \"BRD4\", \"HP1A\", \"LSD1\", \"NR1H3\", \"THRB\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}